Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | PNMT | P11086 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL8858 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL2636 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL1560962 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13747797 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13747801 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Dextroamphetamine SCHEMBL8859 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL15094242 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL9673275 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13746679 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL4781164 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11554103-B2 | Compositions and methods to reduce pharmaceutical-induced toxicity | NORTHWESTERN UNIVERSITY (US) | 2023-01-17 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-10258738-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10258778-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180153839-A1 | COMPOSITIONS AND METHODS TO REDUCE PHARMACEUTICAL-INDUCED TOXICITY | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20170224911-A1 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS, PARKINSON'S DISEASE, AIDS, EPILEPSY, ATTENTION DEFICIT DISORDER, NICOTINE ADDICTION, CANCER, HEADACHE AND PAIN CONTROL, ASTHMA, ANGINA, HYPERTENSION, DEPRESSION, COLD, FLU AND THE LIKE | MORNINGSIDE VENTURE INVESTMENTS LIMITED | 2017-08-10 | — | — | US | disclosed |
| US-20170182299-A1 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS, PARKINSON'S DISEASE, AIDS, EPILEPSY, ATTENTION DEFICIT DISORDER, NICOTINE ADDICTION, CANCER, HEADACHE, AND PAIN CONTROL, ASTHMA, ANGINA, HYPERTENSION, DEPRESSION, COLD, FLUE AND THE LIKE | MORNINGSIDE VENTURE INVESTMENTS LIMITED | 2017-06-29 | — | — | US | disclosed |
| US-9669199-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20110021564-A1 | METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR | LCS GROUP, LLC (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100166889-A1 | METHOD OF TREATING DEPRESSIVE DISORDERS | LCS GROUP, LLC (US) | 2010-07-01 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220092-A1 | Overcoming active agent tolerance, which may be experienced from continuous administration, improve patient compliance, and in some cases reducing the amount of drug needed per dose due to advantages of biosynchronization | CHRONO THERAPEUTICS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2008054788-A9 | TRANSDERMAL DELIVERY TECHNIQUES FOR DRUGS, NUTRACEUTICALS AND OTHER ACTIVE SUBSTANCES | CHRONO THERAPEUTICS INC (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008054788-A2 | TRANSDERMAL DELIVERY TECHNIQUES FOR DRUGS, NUTRACEUTICALS AND OTHER ACTIVE SUBSTANCES | CHRONO THERAPEUTICS, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153839-A1 | COMPOSITIONS AND METHODS TO REDUCE PHARMACEUTICAL-INDUCED TOXICITY | PARK7, SNCA, PRNP | SLC6A2 850/4885SLC6A3 197/4885TAAR1 4178/4885 |
| US-11554103-B2 | Compositions and methods to reduce pharmaceutical-induced toxicity | PARK7, SNCA, PRNP | SLC6A2 850/4885SLC6A3 197/4885TAAR1 4178/4885 |
| US-20110021564-A1 | METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR | COMT, MC4R, SLC6A4 | SLC6A2 38/4885SLC6A3 6/4885TAAR1 229/4885 |
| US-20100166889-A1 | METHOD OF TREATING DEPRESSIVE DISORDERS | HTR5A, SLC6A4, HTR4 | SLC6A2 7/4885SLC6A3 12/4885TAAR1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.